UF Health is using the knowledge gained from pharmacogenomics research to advance health care for our patients. Pharmacogenetic testing provides information about a person’s genetic profile that can be used to help identify the right medicine and the right dose, ideally before a patient starts taking a medication. UF Health providers at hospitals and clinics in Gainesville and Jacksonville are using genetic information alongside a patient’s medical history to inform treatment decisions in areas such as cancer, heart disease, gastrointestinal disorders and pain management.
Pharmacogenomics Consultation Service
The UF College of Pharmacy operates one of the nation’s first outpatient pharmacogenetics consultation service (MyRx) for UF Health. The virtual service brings pharmacogenetic testing to providers across the state of Florida.
Fast Facts
13,000+ patients genotyped
7 clinical implementations
23 hospitals and clinics have implemented pharmacogenomics testing
Clinical Implementations
JUNE 2012
CYP2C19 – clopidogrel (Gainesville)
CYP2C19 testing was implemented to predict clopidogrel response in patients undergoing percutaneous coronary intervention at UF Health Shands Hospital.
FEBRUARY 2014
TPMT – thiopurines
TPMT genetic testing was implemented to predict response for patients taking a group of drugs known as thiopurines. Adult and pediatric patients with certain types of bowel or joint disorders and acute lymphoblastic leukemia commonly take thiopurines.
JULY 2014
IFNL3-PEG-IFNα
IFNL3 testing was implemented to predict the PEG IFN-α-based drug regimen response for gastroenterology patients.
MAY 2015
CYP2D6 – opioids
CYP2D6 testing was implemented to predict the response of pain management patients taking multiple opioids including tramadol, codeine, hydrocodone and oxycodone.
april 2016
CYP2C19 – clopidogrel (Jacksonville)
CYP2C19 testing was implemented to predict clopidogrel response in patients undergoing percutaneous coronary intervention at UF Health Jacksonville
OCTOBER 2016
CYP2D6 / CYP2C19 – SSRIs
CYP2D6 and CYP2C19 testing was implemented to predict response for psychiatric patients taking a group of drugs known as selective serotonin reuptake inhibitors, or SSRIs.
JANUARY 2017
CYP2C19 – PPIs
CYP2C19 testing was implemented to predict response for gastroenterology patients taking a group of drugs known as proton pump inhibitors.
2017
PGx Consult Clinic
2018
CYP2D6 – Opioids (Surgery)
2019
Panel/Preemptive Testing
2019
Oncology Supportive Care
2019
TPMT/NUDT15-Thiopurines
2020
CYP2C9-NSAIDs
2022
MyRx
2023
SLC01B1-statins
2023
Genomic Indicators
What is Pharmacogenetics?
Identify the best medicine for you
What is pharmacogenetics?
Pharmacogenetics can affect response, increase effectiveness and decrease side effects to different medications.
Play Video
Infectious Disease Pharmacokinetics Laboratory
under the direction of Dr. Charles Peloquin
Infectious Disease Pharmacokinetics Laboratory
The Infectious Disease Pharmacokinetics Laboratory is focused clinically on the treatment of patients with serious infections, including tuberculosis, HIV and fungal infections.
The Future of Precision Medicine at UF Health
a new era of genetic medicine
Reengineering the clinical environment for precision medicine at UF Health
In 2019, the UF Health Precision Medicine Program launched a multi-gene pharmacogenetics panel developed by UF Health Pathology Laboratories. It examines multiple drugs, multiple genes and, eventually, diseases to personalize drug therapy and disease risk assessment around an individual’s genetic profile.
